Read this company snapshot
Daily valuation snapshot
Cellectar Biosciences INC NEW: source evidence dated 2026-10-09.
- Daily close (USD)
- $1.45
- Market capitalization (USD)
- $13,705,556.6
- Price / earnings (TTM)
- Not reported
- Price / book
- 0.46
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research CLRB in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research CLRB in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing CLRB with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $1.45 |
| Market capitalization (USD) | $13,705,556.6 |
| Price / earnings (TTM) | Not reported |
| Price / book | 0.46 |
No matching rows. Clear the filter to see all records.
Read CLRB's valuation metrics
Company size
Cellectar Biosciences INC NEW's recorded market capitalization is $13,705,556.6. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
CLRB's recorded price-to-book ratio is 0.46. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Cellectar Biosciences INC NEW with Aurora
Use the snapshot above to ask a specific question about CLRB. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow CLRB's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.